Treatment of moderate to severe pediatric asthma
Annals of Allergy, Asthma & Immunology
July 2016 Vol. 117, Issue 1, p17–20
Participants will be able to demonstrate increased knowledge of the clinical treatment of allergy/asthma/immunology and how new information can be applied to their own practices.
Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Planning Committee Members:
Lakiea S. Wright, MD, MAT, MPH (Author)
Wanda Phipatanakul, MD, MS (Author)
Jonathan A. Bernstein, MD (Annals CME Subcommittee)
Guha Krishnaswamy, MD (Annals CME Subcommittee)
John J. Oppenheimer, MD (Annals CME Subcommittee, Associate Editor)
Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)
Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)
Physicians involved in providing patient care in the field of allergy/asthma/immunology
At the conclusion of this activity, participants should be able to:
- Describe the indications for use of omalizumab in pediatric asthma
- Discuss the evidence that supports the use of omalizumab in pediatric asthma
- Review the literature on monoclonal antibodies that are under investigation in clinical trials for treatment of pediatric asthma R
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance
- 1.00 MOC